1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Day One Biopharmaceuticals's 1-Year ROIIC % for the quarter that ended in Dec. 2025 was 3,966.84%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Day One Biopharmaceuticals's 1-Year ROIIC % or its related term are showing as below:
DAWN's 1-Year ROIIC % is not ranked
in the Biotechnology industry.
Industry Median: -8.92
vs DAWN: 3966.84
Day One Biopharmaceuticals (NAS:DAWN) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Day One Biopharmaceuticals 1-Year ROIIC % Related Terms
Day One Biopharmaceuticals 1-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DAWN vs TYRA, DFTX, MLYS: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Day One Biopharmaceuticals's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's 1-Year ROIIC % falls into.
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -125.437725 (Dec. 2025) - -217.27 (Dec. 2024) )
/
( 25.574 (Dec. 2025) - 23.259 (Dec. 2024) )
=
91.832275
/
2.315
=
3,966.84%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Day One Biopharmaceuticals (DAWN) has a 1-Year ROIIC % of 3,966.84 as of Dec. 2025. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Day One Biopharmaceuticals and its competitors.
Is Day One Biopharmaceuticals' 1-Year ROIIC % too high?
Day One Biopharmaceuticals' current 1-Year ROIIC % is 3,966.84. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' 1-Year ROIIC % compare to TYRA and DFTX?
Day One Biopharmaceuticals' 1-Year ROIIC % of 3,966.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current 1-Year ROIIC % is 3,966.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current 1-Year ROIIC % of 3,966.84. The current 1-Year ROIIC % is 3,966.84. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current 1-Year ROIIC % is 3,966.84 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score
Get the complete analysis for DAWN
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DAWN has been successfully added to your 
